IndraLab

"Hill et al. have reported on the synthesis and biological evaluation of nine sulfonylureas that inhibit NLRP3 activation in mouse bone marrow-derived macrophages in an effective dose-dependent manner."

"Other sulfonylureas, such as glyburide, sulofenur, and glimepiride, also inhibit NLRP3 signaling [106,107]."

"We report the synthesis and biological evaluation of nine sulfonylureas that inhibit NLRP3 activation in murine bone-marrow- derived macrophages in a potent, dose dependent manner."

"Different classes of oral hypoglycemic drugs modulate NLRP3 inflammasome activity through various mechanisms: sulfonylureas inhibit NLRP3 activation and reduce inflammatory cytokine levels; sodium-glucose co-transporter 2 inhibitors (SGLT2i) suppress inflammasome activity by reducing oxidative stress and modulating intracellular signaling pathways; dipeptidyl peptidase-4 inhibitors mitigate inflammasome activation, protecting against renal and vascular complications; glucagon-like peptide-1 receptor agonists attenuate NLRP3 activity, reducing inflammation and improving metabolic outcomes; alpha-glucosidase inhibitors and thiazolidinediones exhibit anti-inflammatory properties by directly inhibiting NLRP3 activation."

"Nine different sulfonylureas have been reported to inhibit the activation of NLRP3 in mouse bone marrow-derived macrophages in a dose-dependent manner."

"External use of sulfonylureas (such as Glibenclamide) can inhibit the activation of NLRP3, up-regulate IL-10, IGF-1 and TGF-β, down-regulate IL-1β, IL-18, and TNF-α, and as a result down-regulate the pro-inflammatory M1 phenotype, up-regulate the pro-healing M2 phenotype and promote wound healing in DM mice (Mirza et al., 2014)."

"As mentioned above, the type 2 diabetes mellitus (T2DM) drug, glyburide, is also a sulfonylurea that inhibits NLRP3 [ 12 ] and several other sulfonylureas, such as sulofenur and glimepiride, can also [MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

"As mentioned above, the type 2 diabetes mellitus (T2DM) drug, glyburide, is also a sulfonylurea that inhibits NLRP3 [ 12 ] and several other sulfonylureas, such as sulofenur and glimepiride, can also [MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"

"Small molecules, such as sulfonylurea used for the treatment of T2D also inhibit NLRP3."